NO20074859L - Nanopartikulaere formuleringer av docetaxel og analoger derav - Google Patents

Nanopartikulaere formuleringer av docetaxel og analoger derav

Info

Publication number
NO20074859L
NO20074859L NO20074859A NO20074859A NO20074859L NO 20074859 L NO20074859 L NO 20074859L NO 20074859 A NO20074859 A NO 20074859A NO 20074859 A NO20074859 A NO 20074859A NO 20074859 L NO20074859 L NO 20074859L
Authority
NO
Norway
Prior art keywords
docetaxel
analogs
nanoparticulate formulations
nanoparticulate
formulations
Prior art date
Application number
NO20074859A
Other languages
English (en)
Inventor
Elaine Liversidge
Gary Liversidge
Scott Jenkins
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of NO20074859L publication Critical patent/NO20074859L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det er beskrevet sammensetninger av nanopartikulært docetaxel eller en analog derav. Sammensetningene som omfatter et nanopartikulært docetaxel eller en analog derav, og minst én overflatestabilisator, kan brukes ved behandlingen av cancer.
NO20074859A 2005-02-24 2007-09-24 Nanopartikulaere formuleringer av docetaxel og analoger derav NO20074859L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65593405P 2005-02-24 2005-02-24
PCT/US2006/006535 WO2006091780A2 (en) 2005-02-24 2006-02-24 Nanoparticulate formulations of docetaxel and analogues thereof

Publications (1)

Publication Number Publication Date
NO20074859L true NO20074859L (no) 2007-11-26

Family

ID=36928029

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074859A NO20074859L (no) 2005-02-24 2007-09-24 Nanopartikulaere formuleringer av docetaxel og analoger derav

Country Status (14)

Country Link
US (1) US20060188566A1 (no)
EP (1) EP1855659A2 (no)
JP (1) JP2008531591A (no)
KR (1) KR20080003322A (no)
CN (1) CN101160118A (no)
AU (1) AU2006216640A1 (no)
BR (1) BRPI0608173A2 (no)
CA (1) CA2598441A1 (no)
EA (1) EA015987B1 (no)
IL (1) IL185292A0 (no)
MX (1) MX2007010394A (no)
NO (1) NO20074859L (no)
WO (1) WO2006091780A2 (no)
ZA (1) ZA200706783B (no)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2377318T3 (es) 2002-09-06 2012-03-26 Cerulean Pharma Inc. Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
CA2563533C (en) * 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
LT3311805T (lt) 2005-08-31 2020-04-27 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus
EP3527202A1 (en) * 2005-08-31 2019-08-21 Abraxis BioScience, LLC Compositions and methods for preparation of poorly water soluble drugs with increased stability
CZ300305B6 (cs) * 2005-12-20 2009-04-15 Heaton, A. S. Farmaceutická kompozice obsahující derivát taxanu se zlepšenou terapeutickou úcinností
SG170047A1 (en) * 2006-05-30 2011-04-29 Elan Pharma Int Ltd Nanoparticulate posaconazole formulations
JP2009543797A (ja) * 2006-07-10 2009-12-10 エラン ファーマ インターナショナル，リミティド ナノ粒子ソラフェニブ製剤
NZ549831A (en) * 2006-09-11 2009-03-31 Auckland Uniservices Ltd Combination of docetaxel and a nitrophenyl phosphate derivative for the treatment of cancer
BRPI0717721A2 (pt) * 2006-11-28 2013-10-29 Marinus Pharmaceuticals "partículas complexadas de drogas, composição farmacêutica, uso de uma composição farmacêutica, partículas complexadas de droga estabilizadas no tamanho, método para a preparação de partículas estabilizadas da droga, composição farmacêutica sólida, comprimido oral ingerível e composição líquida em nanopartículas estabilizadas no tamanho"
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
WO2008092084A2 (en) * 2007-01-26 2008-07-31 Centocor, Inc. Injectable non-aqueous suspension with high concentration of therapeutic agent
WO2008118754A2 (en) * 2007-03-23 2008-10-02 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods for making the same
WO2009002425A2 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without tween 80
MX2010002179A (es) * 2007-08-24 2010-04-27 Stichting Het Nl Kanker I Composicion para el tratamiento de enfermedades neoplasicas.
US9089544B2 (en) * 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
WO2009047794A2 (en) * 2007-10-01 2009-04-16 Intas Pharmaceuticals Limited Taxane derivative composition
WO2009087678A2 (en) * 2007-12-24 2009-07-16 Sun Pharma Advanced Research Company Limited Nanodispersion
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
TW200942233A (en) * 2008-04-10 2009-10-16 Abraxis Bioscience Llc Compositions of hydrophobic taxane derivatives and uses thereof
MX2010011165A (es) * 2008-04-10 2011-02-22 Abraxis Bioscience Llc Composiciones de derivados de taxano hidrofobos y sus usos.
KR101814186B1 (ko) 2008-09-17 2018-03-14 키아스마 인코포레이티드 약제학적 조성물 및 연관된 투여방법
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
CA2782655A1 (en) * 2009-01-06 2010-07-15 Pharmanova, Inc. Nanoparticle pharmaceutical formulations
EP3167875A1 (en) 2009-05-27 2017-05-17 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate meloxicam compositions
EP2442805A4 (en) * 2009-06-19 2012-11-21 Sun Pharma Advanced Res Co Ltd NANODISPERSION OF A MEDICINE AND METHOD FOR PREPARING THE SAME
KR101007925B1 (ko) * 2009-10-07 2011-01-14 건일제약 주식회사 경구용 지질 나노입자 및 그의 제조방법
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US20120225825A1 (en) * 2009-11-23 2012-09-06 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
FR2952936B1 (fr) * 2009-11-26 2011-11-25 Flamel Tech Polymere de type acrylique ou methacrylique comprenant des greffons alpha-tocopherol
CN101773480B (zh) * 2010-01-19 2012-03-14 山东大学 含有多西他赛的纳米结晶制剂及其冻干剂的制备方法
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
MX2012011155A (es) * 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
US10842770B2 (en) 2010-05-03 2020-11-24 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
ES3055223T3 (en) 2012-05-03 2026-02-10 Alcon Inc Pharmaceutical nanoparticles showing improved mucosal transport
JP6360039B2 (ja) * 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP2863897B1 (en) * 2012-06-21 2019-06-19 Phosphorex Inc. Nanoparticles of indirubin, derivatives thereof and methods of making and using same
US9018246B2 (en) * 2012-09-05 2015-04-28 Lp Pharmaceutical (Xiamen) Co., Ltd. Transmucosal administration of taxanes
JO3685B1 (ar) * 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
CN105050585A (zh) * 2013-03-04 2015-11-11 Vtv治疗有限责任公司 稳定的葡萄糖激酶活化剂组合物
CN103100087B (zh) * 2013-03-04 2014-09-10 中国科学院上海硅酸盐研究所 磷酸钙/有机物复合纳米颗粒的制备方法
CN104394898B (zh) * 2013-05-02 2017-10-13 卡迪奥诺沃姆有限公司 球囊表面涂层
US20160143857A1 (en) * 2013-06-27 2016-05-26 Universite De Namur Hybrid alginate-silica beads and method for obtaining them
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
AU2015212726B2 (en) * 2014-02-03 2018-02-01 Apurano Pharmaceuticals Gmbh Nanosuspension of natural materials and preparation method thereof
CR20170031A (es) * 2014-10-06 2017-05-22 Mayo Found For Medical Educaction And Res Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
JP6706261B2 (ja) 2014-12-01 2020-06-03 インノウプ、ファルマ、ソシエダッド、リミターダＩｎｎｏｕｐ Ｆａｒｍａ， Ｓ．Ｌ． 化合物を封入するためのナノ粒子、その製造および使用
WO2016126830A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
CA3026454C (en) 2015-06-04 2023-07-04 Crititech, Inc. Collection device and methods for use
ES3055492T3 (en) 2015-09-16 2026-02-12 Dfb Soria Llc Delivery of drug nanoparticles and methods of use thereof
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
CN105581996B (zh) * 2016-02-23 2018-03-27 广西梧州制药（集团）股份有限公司 一种去水卫矛醇微囊及其制备方法
EP3854381A1 (en) * 2016-04-04 2021-07-28 Crititech, Inc. Methods for solid tumor treatment
TWI754666B (zh) * 2016-10-05 2022-02-11 國立大學法人東北大學 於淋巴行性藥劑投予法中有效之藥劑
CN106588902B (zh) * 2016-11-29 2019-07-02 昌吉学院 一种紫杉醇抗癌药物、其制备方法及应用
WO2018170196A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
CA3063420A1 (en) 2017-06-09 2018-12-13 Crititech, Inc. Treatment of epithelial cysts by intracystic injection of antineoplastic particles
WO2018231908A1 (en) * 2017-06-14 2018-12-20 Crititech, Inc. Methods for treating lung disorders
KR20250057947A (ko) 2017-10-03 2025-04-29 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
EP3765035A4 (en) 2018-03-16 2021-10-27 DFB Soria, LLC TOPICAL THERAPY FOR THE TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND COLD CANCER USING TAXANE NANOPARTICLES
US20210023041A1 (en) * 2018-04-11 2021-01-28 Zhuhai Beihai Biotech Co., Ltd. Formulations and compositions of docetaxel
CN110292574A (zh) * 2019-08-02 2019-10-01 江苏红豆杉药业有限公司 一种抗肠癌药物组合物及其应用
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
JP7606633B2 (ja) * 2022-04-14 2024-12-25 ウィズダム・ファーマスーティカル・カンパニー・リミテッド 医薬組成物及びアプレピタント注射液並びに凍結乾燥粉末注射剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4638067A (en) * 1982-09-09 1987-01-20 Warner-Lambert Co. Antibacterial agents
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US5834025A (en) * 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US6153225A (en) * 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
DE69805860T2 (de) * 1998-08-21 2003-01-02 Pharmachemie B.V., Haarlem Wasserlösliche ähnliche verbindungen und medicament-vorstufe von paclitaxel
IL143197A0 (en) * 1998-11-20 2002-04-21 Rtp Pharma Inc Dispersible phospholipid stabilized microparticles
GB2355656B (en) * 1999-08-17 2004-04-07 Galena As Pharmaceutical compositions for oral and topical administration
WO2002030466A2 (en) * 2000-10-11 2002-04-18 Purdue Research Foundation Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof
KR100774366B1 (ko) * 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
WO2003080027A1 (en) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
EP2283864A1 (en) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
WO2004098570A1 (en) * 2002-10-30 2004-11-18 Spherics, Inc. Nanoparticulate bioactive agents
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles

Also Published As

Publication number Publication date
AU2006216640A1 (en) 2006-08-31
WO2006091780A3 (en) 2007-01-11
MX2007010394A (es) 2008-02-19
JP2008531591A (ja) 2008-08-14
ZA200706783B (en) 2008-10-29
EP1855659A2 (en) 2007-11-21
US20060188566A1 (en) 2006-08-24
CN101160118A (zh) 2008-04-09
EA015987B1 (ru) 2012-01-30
BRPI0608173A2 (pt) 2010-11-09
WO2006091780A2 (en) 2006-08-31
EA200701793A1 (ru) 2008-02-28
IL185292A0 (en) 2008-02-09
CA2598441A1 (en) 2006-08-31
KR20080003322A (ko) 2008-01-07

Similar Documents

Publication Publication Date Title
NO20074859L (no) Nanopartikulaere formuleringer av docetaxel og analoger derav
NO20075148L (no) Anti-proliferativ kombinasjonsterapi med andvendelse av visse platinum-baserte kjemoterapeutiske midler og taxaner
BRPI0716210A2 (pt) Métodos, composições e aparelhos para tratar feridas com pressões diferentes da atmosférica
WO2009009620A3 (en) Acellular tissue matrix compositions for tissue repair
ATE499109T1 (de) Zusammensetzung zur proteasomhemmung
EP2450040A3 (en) Compositions and kits for treating influenza
LTPA2018502I1 (lt) Per burną vartojamos kladribino kompozicijos
UA104605C2 (uk) Аналоги глюкагону
ATE553792T1 (de) Medizinische vorrichtungen mit verbundstoffen
ECSP109852A (es) Uso de homo y copolímeros para la estabilización de formulaciones de principios activos
CL2007001992A1 (es) Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege
BRPI0815577A2 (pt) Peptídeo foxm1 e agente medicinal compreendendo o mesmo.
IL196965A (en) Analogues of (r, r) or (s, r) phenoterol, their pharmaceutical composition containing them and their use for the treatment of heart failure
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
IL186127A (en) Subcutaneous preparations for the treatment of depression and methods for their preparation
CL2008002353A1 (es) Compuestos derivados de 7h-indolo[2,1-a][2]benzazepina; composicion farmaceutica; y uso en el tratamiento de la hepatitis c.
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
CL2007002671A1 (es) Compuestos derivados de octahidro-pirrolo[3,4-c]pirrol; composicion farmaceutica que la comprende; y uso del compuesto en el tratamiento del vih, sida o arc.
KR102560772B9 (ko) 신규한 이온화지질 및 이를 이용한 지질나노입자 조성물
CL2007002619A1 (es) Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion.
NO20080133L (no) Azolopyridin-2-on derivater som lipase og fosfolipaseinhibitorer
AR073057A1 (es) Combinaciones insecticidas de abamectina y ciflumetofeno y composiciones que las comprenden.
DK1646378T3 (da) Farmaceutiske præparater omfattende ascorbinsyre til behandling af superinfektion med svamp og recidiv svamp
BRPI0821116A2 (pt) Composto, composição farmacêutica que o contem, uso deste e método para tratar qualquer mamífero afetado por câncer
EA200601596A1 (ru) Улучшенный состав 6-меркаптопурина

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application